Zhang Bofang, Zhang Jing, Liu Gen, Guo Xin, Liu Xiaopei, Chen Jing
Department of Cardiology, Renmin Hospital of Wuhan University, Hubei Key Laboratory of Cardiology, Cardiovascular Research Institute, Wuhan University, Wuhan, China.
Department of Cardiology, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, China.
Front Cardiovasc Med. 2022 Apr 29;9:870999. doi: 10.3389/fcvm.2022.870999. eCollection 2022.
Even after the glucose level returns to normal, hyperglycemia-induced cardiac dysfunction as well as reactive oxygen species (ROS) generation, inflammatory responses, and apoptosis continued deterioration, showing a long-lasting adverse effect on cardiac function and structure. We aimed to unveil the molecular and cellular mechanisms underlying hyperglycemia-induced persistent myocardial injury and cardiac dysfunction.
Recently, the accumulated evidence indicated epigenetic regulation act as a determining factor in hyperglycemia-induced continuous cardiovascular dysfunction. As an important histone demethylase, the expression of lysine-specific demethylase 3A (KDM3A) was continually increased, accompanied by a sustained decline of H3K9me2 levels in diabetic myocardium even if received hypoglycemic therapy. Besides, by utilizing gain- and loss-of-functional approaches, we identified KDM3A as a novel regulator that accelerates hyperglycemia-mediated myocardial injury by promoting ROS generation, aggregating inflammatory reaction, and facilitating cell apoptosis and . The KDM3A inhibition could significantly ameliorate the adverse effect of hyperglycemia in both diabetes model and diabetic intensive glycemic control model. Mechanically, our data uncovered that KDM3A could promote the expression and transcriptional activity of nuclear factor kappa-B (NF-κB/P65), and the succedent rescue experiments further verified that KDM3A regulates hyperglycemia-induced myocardial injury in an NF-κB/P65 dependent manner.
This study revealed histone-modifying enzymes KDM3A drives persistent oxidative stress, inflammation, apoptosis, and subsequent myocardial injury in the diabetic heart by regulating the transcription of NF-κB/P65.
即使血糖水平恢复正常,高血糖诱导的心脏功能障碍以及活性氧(ROS)生成、炎症反应和细胞凋亡仍会持续恶化,对心脏功能和结构产生长期不良影响。我们旨在揭示高血糖诱导的持续性心肌损伤和心脏功能障碍的分子和细胞机制。
最近,越来越多的证据表明表观遗传调控是高血糖诱导的持续性心血管功能障碍的决定性因素。作为一种重要的组蛋白去甲基化酶,赖氨酸特异性去甲基化酶3A(KDM3A)的表达持续增加,即使接受降糖治疗,糖尿病心肌中H3K9me2水平仍持续下降。此外,通过功能获得和功能缺失方法,我们确定KDM3A是一种新型调节因子,它通过促进ROS生成、聚集炎症反应和促进细胞凋亡来加速高血糖介导的心肌损伤。KDM3A抑制可显著改善糖尿病模型和糖尿病强化血糖控制模型中高血糖的不良影响。从机制上讲,我们的数据发现KDM3A可以促进核因子κB(NF-κB/P65)的表达和转录活性,随后的挽救实验进一步证实KDM3A以NF-κB/P65依赖的方式调节高血糖诱导的心肌损伤。
本研究揭示组蛋白修饰酶KDM3A通过调节NF-κB/P65的转录,驱动糖尿病心脏中持续的氧化应激、炎症、细胞凋亡以及随后的心肌损伤。